retatrutide in australia Research Guide: What the Phase 2 Trial Data Reported (2026) ALERT: Health officials have warned

Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage

Published in The Lancet: June 2026

Retatrutide is therefore widely studied in models examining obesity-related metabolic risk factors, including insulin resistance and dysregulated energy balance

How many calories should you eat on GLP-1 medications